Proviron Bloodwork Guide: Exactly What to Test Before, During, and After Mesterolone and How to Read Every Result

Adding Proviron to your protocol without monitoring bloodwork is flying blind. Mesterolone alters the relationship between total testosterone, free testosterone, SHBG, and the androgen-to-oestrogen ratio. These changes are measurable, predictable, and the entire basis for dose adjustment. Yet no guide online tells you exactly which markers to test, when to test them, what Proviron-specific changes to expect, and what each result means for your next decision. This guide does. Hemi Pharma UK supplies pharmaceutical-grade mesterolone, and informed use starts with knowing what your blood is telling you.

What Bloodwork Should You Pull Before Starting Proviron?

Your baseline panel establishes the reference point against which all future results are compared. Without it, you cannot distinguish Proviron-induced changes from pre-existing values. The baseline should be taken while you are on your stable TRT or cycle protocol, at trough (immediately before your next testosterone injection), with no variables changed for at least four weeks prior. The panel includes seven markers.

Total testosterone. This is your starting reference. On TRT, a trough reading between 15 and 30 nmol/L is typical depending on dose and ester. After adding Proviron, total testosterone often drops slightly because the free fraction is being cleared faster (free testosterone has a half-life of approximately 10 minutes versus hours for SHBG-bound testosterone). Understanding your baseline total prevents you from panicking when this predictable decline appears.

Free testosterone. This is the marker Proviron is designed to change. Measure it directly if your laboratory offers equilibrium dialysis or calculated free testosterone using the Vermeulen equation, which requires total testosterone, SHBG, and albumin. Fiers, Wu, Moghetti, Vanderschueren, Lapauw and Kaufman (2018) reassessed free testosterone calculation methods using direct equilibrium dialysis with liquid chromatography-tandem mass spectrometry and concluded that the Vermeulen equation, although it overestimates free testosterone levels, is the most robust approximation, largely independent of SHBG, albumin, and testosterone levels (Journal of Clinical Endocrinology and Metabolism, 103(6), 2167-2174). If your laboratory uses the analog free testosterone assay (sometimes called “direct” free testosterone), be aware that it is less accurate than calculated or dialysis methods, particularly at extreme SHBG levels.

SHBG. This is the second marker Proviron directly affects. Your baseline SHBG determines how much displacement potential mesterolone has. Men with SHBG above 40 nmol/L will see the most dramatic free testosterone improvement. Men with SHBG below 25 nmol/L may see minimal change because there is less binding to displace. SHBG also rises with age (approximately 1.2% per year after 40), thyroid hormone elevation, and liver conditions, so it contextualises the rest of the panel.

Oestradiol (sensitive assay). Request the sensitive oestradiol assay (LC-MS/MS), not the standard immunoassay, which is designed for female ranges and is unreliable in men. Your baseline oestradiol establishes the reference for assessing whether Proviron’s ratio-shifting effect is producing functional oestrogen deficit symptoms. If your baseline E2 is already low (below 60 pmol/L), adding Proviron carries higher risk of the ratio trap.

PSA (prostate-specific antigen). Baseline PSA is mandatory before starting any androgen. If your PSA is above 4.0 ng/mL or has risen more than 0.75 ng/mL in the past year, investigate before adding mesterolone. The Bayer SmPC states that regular prostate examinations should be carried out as precautionary measures during treatment.

Liver enzymes (ALT, AST, GGT). Mesterolone is not hepatotoxic, but baseline liver values establish that any future elevation is not attributable to Proviron. If you are using other oral compounds (oxandrolone, stanozolol, oxymetholone), this distinction matters.

Lipid panel (total cholesterol, LDL, HDL, triglycerides). Baseline lipids allow you to assess whether Proviron produces any lipid disturbance at your dose. The Nikkanen (1979) data showed no lipid changes at 75mg daily for six months in healthy active men, but individual responses vary, and the Casquero et al. (2008) preclinical data suggests dose and activity level modulate lipid effects.

When Should You Pull Follow-Up Bloodwork After Starting Proviron?

The first follow-up panel should be taken at four to six weeks after starting Proviron at a stable dose. Mesterolone reaches steady state within approximately three days (five half-lives of the 12-to-13-hour parent compound), but the downstream effects on SHBG suppression, free testosterone equilibrium, and symptom response take longer to stabilise. Four weeks is the minimum for meaningful data. Six weeks is preferable.

Take the blood sample at trough for your testosterone injection (same timing as baseline) and at a consistent time relative to your Proviron dose. If you take Proviron at 8am, pulling blood at 7am (before the morning dose) gives you trough mesterolone levels. If you pull blood at 10am (two hours after dosing), you are measuring near-peak mesterolone levels. Either approach is valid as long as you are consistent between baseline and follow-up.

Subsequent panels should be pulled at 12-week intervals during ongoing use, then annually once your protocol is stable and markers are within acceptable ranges.

What Changes Should You Expect to See on Bloodwork After Adding Proviron?

Total testosterone: expect a mild decrease, typically 5 to 15%. This is not suppression of production (your exogenous testosterone dose has not changed). It reflects accelerated clearance of free testosterone. When SHBG releases testosterone into the free fraction, that free testosterone is metabolised faster than SHBG-bound testosterone. The body is using testosterone more rapidly, not producing less of it.

Free testosterone: expect an increase, typically 15 to 40% depending on your starting SHBG level. Men with high baseline SHBG (above 45 nmol/L) see the largest increases. Men with low baseline SHBG (below 25 nmol/L) see the smallest. If free testosterone has not increased meaningfully at four to six weeks, your dose may be insufficient, your SHBG may already be low, or your product may be underdosed.

SHBG: expect a decrease, typically 10 to 30%. Mesterolone suppresses SHBG through two mechanisms: competitive displacement at the binding protein and direct suppression of hepatic SHBG synthesis via the first-pass effect. The magnitude of SHBG reduction correlates with the magnitude of free testosterone increase.

Oestradiol: expect minimal change. Mesterolone does not inhibit aromatase and does not reduce oestrogen production. If your oestradiol drops significantly after adding Proviron, look for another explanation (reduced testosterone dose, added AI, weight loss increasing SHBG and reducing aromatisation substrate). If your oestradiol reading is unchanged but you have low-oestrogen symptoms, you are experiencing the ratio trap described in our guide to Proviron and oestrogen balance.

PSA: expect no significant change at 25 to 50mg daily. Any increase greater than 0.5 ng/mL from baseline warrants monitoring at shorter intervals. Any increase above 4.0 ng/mL warrants investigation and potential discontinuation.

Liver enzymes: expect no change attributable to mesterolone. If ALT or AST rise, investigate other causes (other oral steroids, alcohol, medication, illness).

Lipids: expect no clinically significant change at 25 to 75mg daily in active men, consistent with the Nikkanen human data. If HDL drops more than 10% from baseline, consider whether other compounds in your protocol (particularly 17-alpha-alkylated orals) are the cause.

How Do You Interpret Bloodwork That Does Not Match Expected Changes?

Total testosterone dropped but free testosterone did not rise. This suggests SHBG was already low before adding Proviron, meaning there were few binding sites to displace. Alternatively, the Proviron may be underdosed. Verify product quality through the Hemi Pharma lab results page and the QR code on your blister pack.

SHBG did not change. Mesterolone at 25mg daily may be insufficient to produce a measurable SHBG reduction in men with very high SHBG (above 60 nmol/L). Increasing to 50mg daily is the next step. If SHBG remains unchanged at 50mg daily, the compound may not be the right tool for your specific SHBG issue, and other interventions (boron supplementation, nettle root extract, or addressing the underlying cause of elevated SHBG) may be needed.

Oestradiol dropped significantly. If you did not change your AI dose, something else is driving the oestrogen decline. Possibilities include weight loss (less adipose tissue means less aromatase), reduced injection frequency, or a change in body composition. The drop is not caused by Proviron directly.

PSA rose. Any PSA rise after adding an androgen should be taken seriously. Retest in four weeks. If the rise is confirmed, discuss with your physician. Do not add more androgens until the cause is determined. All androgens stimulate prostatic tissue; the question is whether the stimulation is benign (common) or indicative of underlying pathology (less common but must be excluded).

What Optional Markers Add Value When Monitoring Proviron?

DHT (dihydrotestosterone). If your laboratory offers serum DHT measurement, it provides direct confirmation that mesterolone is reaching systemic circulation and contributing to DHT-type receptor activation. However, DHT assays are not widely available and are not strictly necessary for Proviron monitoring since the free testosterone and SHBG changes serve as reliable proxy indicators.

Haematocrit and haemoglobin. These are standard TRT monitoring markers. Proviron is not expected to significantly affect haematocrit at clinical doses, but if you are already running near the upper limit (haematocrit above 52%), any additional androgen warrants closer monitoring. A haematocrit above 54% requires intervention (dose reduction, therapeutic phlebotomy, or protocol modification).

Prolactin. If you are using Proviron alongside 19-nortestosterones (nandrolone, trenbolone) and experiencing libido issues despite adequate DHT-type signalling from mesterolone, elevated prolactin from the progestogenic activity of the 19-nor compound may be the remaining cause. Prolactin testing helps distinguish DHT-deficiency libido loss (which Proviron addresses) from prolactin-mediated libido loss (which requires a different intervention).

Full blood count (FBC). Includes red blood cell count, white blood cell count, platelet count, and haematocrit. Running an FBC at baseline and at 12-week intervals provides comprehensive haematological monitoring without additional cost compared to ordering individual markers.

What Does a Well-Optimised Proviron Bloodwork Profile Look Like?

The target profile on TRT plus Proviron at 25 to 50mg daily looks like this. Total testosterone at trough: 15 to 25 nmol/L (may be slightly lower than pre-Proviron baseline, which is expected). Free testosterone: noticeably higher than baseline, ideally above the laboratory’s reference midpoint. SHBG: reduced 10 to 30% from baseline. Oestradiol: mid-range or above (60 to 120 pmol/L on the sensitive assay), with no symptoms of oestrogen excess or deficiency. PSA: stable, no significant rise from baseline. Liver enzymes: within reference range, unchanged from baseline. Lipids: stable, no clinically significant deterioration. Haematocrit: below 52%. Symptoms: improved libido, mood, energy, and well-being compared to pre-Proviron baseline.

If your bloodwork and symptoms match this profile, your protocol is working and your dose is appropriate. Continue monitoring at 12-week intervals for the first year, then annually.

Frequently Asked Questions

What bloodwork do I need before starting Proviron?

Total testosterone, free testosterone (calculated via Vermeulen equation or equilibrium dialysis), SHBG, oestradiol (sensitive LC-MS/MS assay), PSA, liver enzymes (ALT, AST, GGT), and a lipid panel. Take the sample at trough for your testosterone injection, with no protocol changes for at least four weeks prior.

Will Proviron lower my total testosterone on bloodwork?

Yes, typically by 5 to 15%. This reflects accelerated clearance of free testosterone (which has a half-life of approximately 10 minutes once unbound from SHBG), not reduced production. Your exogenous testosterone dose has not changed. The decline in total is offset by the increase in free testosterone, which is the bioactive fraction.

How do I measure the free testosterone increase from Proviron?

Request calculated free testosterone using the Vermeulen equation (requires total testosterone, SHBG, and albumin) or direct measurement by equilibrium dialysis. Avoid the analog “direct” free testosterone assay, which is less accurate, particularly when SHBG is abnormal. Compare the result to your pre-Proviron baseline taken under the same conditions.

Should I test liver enzymes on Proviron?

Yes, at baseline and at follow-up, for completeness and to rule out other causes of elevation. However, mesterolone is not 17-alpha-alkylated and does not cause hepatotoxicity. Any liver enzyme elevation on Proviron is attributable to other factors (other medications, alcohol, other oral steroids like oxymetholone or stanozolol, or underlying liver conditions), not to mesterolone.

How often should I test bloodwork while using Proviron?

Baseline before starting. First follow-up at four to six weeks. Subsequent panels at 12-week intervals during the first year. Annually once the protocol is stable and all markers are within acceptable ranges. More frequent testing if any marker is trending in a concerning direction (rising PSA, declining HDL, elevated haematocrit).